A single head-to-head drug study has done more to reshape pharma valuations than almost any boardroom decision in recent memory.
When researchers compared the two leading GLP-1 treatments directly, Eli Lilly’s (LLY) tirzepatide produced average weight loss of just over 20% in trial participants, a figure that turned heads across the investment world.
By contrast, Novo Nordisk’s (NVO) semaglutide achieved a little under 14% average weight loss in the same study, a meaningful gap that investors have not been willing to ignore.
That performance difference has contributed to a valuation divergence that now borders on extraordinary, with Lilly worth nearly nine times Novo Nordisk by market capitalization.
It is a striking reversal given that Novo Nordisk was the first mover in the GLP-1 category, securing approval for Ozempic as far back as 2017 and building a substantial head start over its rival.
Lilly did not enter the race until 2022, when Mounjaro cleared regulatory hurdles, yet the company’s aggressive clinical results quickly closed what had seemed like an insurmountable gap.
Neither company is a pure-play weight loss business, and both maintain diversified drug portfolios spanning multiple treatment categories, meaning their fortunes are not entirely tied to obesity medications.
The competition between them entered a new phase in 2026 as both firms moved into oral GLP-1 territory, with Novo launching a pill form of Wegovy early in the year and Lilly following with Foundayo within months.
Novo’s oral Wegovy currently leads Lilly’s Foundayo in prescription volumes, though Foundayo has been climbing steadily, and analysts say it is too early to declare a winner in the pill segment.
Novo Nordisk holds roughly 36% of the GLP-1 market, but as that landscape has shifted, investor sentiment has moved sharply in Lilly’s direction, lifting LLY’s share price while NVO’s has declined.
The dynamic reflects a broader pattern in biotech investing, where clinical efficacy data often carries more weight than first-mover advantage when markets are large enough to reward the best-performing product.
Lilly’s rise to a valuation nearly nine times that of a company that once defined the weight loss drug category underscores how quickly competitive positions can shift when the underlying science diverges.
With Foundayo gaining prescription momentum and Lilly’s efficacy data firmly established, the pressure on Novo Nordisk to close the performance gap with future treatments has rarely been greater.
